Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth.

摘要: Bronchopulmonary dysplasia (BPD) remains the most common and serious chronic lung disease of premature infants. Severe BPD complicated with pulmonary hypertension (PH) increases mortality these Riociguat is an allosteric soluble guanylate cyclase stimulator approved by FDA for treating PH in adults. However, it has not been use neonates due to concern adverse effects on long bone growth. To address this we investigated if administration riociguat beneficial preventing hyperoxia-induced injury without side growth newborn rats. Newborn rats were randomized normoxia (21% O2) or hyperoxia (85% exposure groups within 24 hours birth, received placebo once daily intraperitoneal injections during continuous 9 days. In control group, radial alveolar count, mean linear intercept vascular density significantly decreased, pathological hallmarks BPD, accompanied increased inflammatory response. There was also elevated muscularization peripheral vessels, right ventricular systolic pressure hypertrophy indicating PH. decreased inflammation, improved development, inducing cGMP production. Additionally, did affect structure. These data indicate that affecting structure hence, suggests may be a potential novel agent neonates.